Compare BridgeBio Pharma Inc (BBIO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Lufax Holding Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Lufax Holding Ltd trades at $1.56 (market cap $2.41B). The key difference: BridgeBio Pharma Inc is far larger — about 6.8× Lufax Holding Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | LU | |
|---|---|---|
Market Cap | $16.36B | $2.41B |
Sector | Health | Technology |
52-Week High | $90.17 | $4.40 |
52-Week Low | $47.29 | $1.23 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
